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ABSTRACT 
Receiving a cancer diagnosis leads to severe psychological distress. Previous studies have 
shown increased risk for various health consequences following a cancer diagnosis, including 
mental disorders, life-threatening cardiovascular events, and suicide. However, whether the 
severe stress response after a cancer diagnosis impacts cancer progression and healthcare use 
pattern for cancer patients is not clear yet. Furthermore, whether potential interventions, 
including beta-blocking agent treatment and shortened waiting-time during cancer diagnostic 
workup, could reduce such stress response and its related adverse health outcomes needs to 
be investigated. 
In study I, to investigate whether stress-related mental disorders, as indicators of a severe 
stress response to cancer diagnosis, were associated with an increased mortality among 
cancer patients, we performed a prospective cohort study including 244,261 adult cancer 
patients diagnosed during 2004-2009 in Sweden. Stress-related mental disorders diagnosed 
after cancer diagnosis were used as the primary exposure, and cancer-specific mortality was 
used as the main outcome of interest. In this study, an increased cancer-specific mortality was 
found in relation to stress-related mental disorders, especially the first-onset mental disorders. 
In study II, we assessed the impact of stress-related mental disorders on rate of hospital 
admissions after cancer diagnosis, by a prospective cohort study including 218,508 adult 
cancer patients diagnosed between 2004 and 2009 in Sweden. Stress-related mental disorders 
diagnosed from 90 days before to 90 days after cancer diagnosis were associated with an 
increased risk of any hospital admissions as well as hospital admissions for external injuries, 
infections, and cardiovascular diseases from 90 days after cancer diagnosis onward. 
In study III, we explored the role of beta-blocking agent treatment on the risk of severe 
cardiovascular events after cancer diagnosis, in a cohort study of all adult cancer patients 
diagnosed during 2006-2013 in Sweden. Beta-blocking agent treatment during 90 days before 
cancer diagnosis was not found to be associated with a decreased risk of cardiovascular death 
or hospital admission due cardiovascular diseases, either during the 90 days after cancer 
diagnosis or thereafter. 
In study IV, we performed a randomized clinical trial including men clinically evaluated for 
suspected prostate cancer, to quantify the stress experience during the diagnostic workup of 
prostate cancer and assess its association with waiting-time. Patients in the intervention group 
had a fast-track workup with the shortest possible waiting-time, whereas the control group 
received the usual care. We presented baseline data at randomization and follow-up data at 
the first urologist visit, and found that depression symptoms and self-rated sleep quality score 
were reduced among men in the fast-track workup group, compared to the control group. 
In conclusion, stress-related mental disorders diagnosed around cancer diagnosis, as 
indicators of the severe stress response to cancer diagnosis, were associated with an increased 
cancer-specific mortality and increased rate of hospital admission. Beta-blocking agent 
treatment was not associated with a decreased risk of severe cardiovascular events 
immediately following a cancer diagnosis. For men with suspected prostate cancer, a 
shortened waiting-time during the diagnostic workup might lead to reduced risks of 
depression and sleeping problem.  
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1 BACKGROUND 
1.1 Psychological stress and stress response 
American physiologist Walter Cannon first mentioned the modern word ‘homeostasis’ in the 
beginning of the 20th century [1], and a few decades later the synonym ‘stress’ was first used 
with its current meaning and popularized by Hans Selye [2]. The homeostasis is the living 
status all organisms strive to, which is a dynamic balance constantly challenged by intrinsic 
or extrinsic disturbing forces. The disturbing forces are usually called stressors, and the stress 
is defined as a state of threatened homeostasis [3]. All the physiological and behavioral 
responses acting by organisms with the aim to maintain homeostasis during stress are referred 
as ‘stress response’ [4]. When the homeostasis is threatened and the stressor exceeds certain 
severity or threshold, the adaptive systems will be activated and respond to the specific 
stressor functionally [4].  
The stress response is an innate reaction that is evolved to maintain homeostasis and protects 
organism from stressor. The processes take place in both the central nervous system (CNS) 
and various peripheral organs and tissues by the pathways of endocrine and autonomic limbs 
[3]. Through the endocrine limb, arginine vasopressin and corticotropin-releasing hormone 
secreted from hypothalamus stimulates corticotropin secretion from the anterior pituitary, 
which, as consequence, activates the adrenal cortex to release large quantities of 
glucocorticoid hormones [5]. The autonomic nervous system reacts rapidly during stress and 
regulates a range of essential functions through the sympathetic and parasympathetic nervous 
system, including cardiovascular, respiratory, endocrine, and other systems [5]. After being 
activated during stress, these stress pathways stimulate their target systems, leading to 
increased oxygenation and nutrition in brain, heart, and skeletal muscles [6-8].  
However, inappropriate activity or responsiveness of the stress system, in the form of 
overloading or long duration, might impair growth, development, and increase the risk of 
dysfunction in many systems, including mood, endocrine, metabolic, cardiovascular, and 
immune systems [3]. For example, chronic stress is associated with reduced rewarding value 
in mesolimbic dopaminergic system in terms of inhibiting dopamine release in many terminal 
areas, including hypothalamus [9]. The inability to cope with life events, which can increase 
secretion of corticosteroids, has been associated with increased risk for depression, abdominal 
obesity, osteoporosis, and cardiovascular diseases [10]. 
Potential biomarkers of stress response 
Stress response can be measured through interview and self-report measurements. 
Psychological symptoms and disorders that are potentially induced by exposure to stressful 
events are frequently assessed when measuring stress response [11]. Commonly used 
measures for acute and chronic stresses include the Profile of Mood States [12] and the 
Impact of Events Scale [13]. Other instruments have been designed to additionally assess the 
frequency and extent of such symptoms within a specific time period. For example, different 
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instruments are nowadays available in the assessment of acute or chronic stressful events 
[14], including Survey of Recent Life Experiences for major life events, Stockholm Marital 
Stress Scale for stress of marriage, Job Content Questionnaire for work related stress, and 
Bergen Social Relationships Scale for social stress. There are also questionnaires to assess 
coping abilities, personality traits (Type-D personality trait), and psychological and physical 
changes of stress experiences (Perceived Stress Scale).  
Stress response might also be indicated by experiencing severe negative health outcomes. For 
example, suicide attempt or completed suicide [15], diagnosis of a psychiatric disorder [16], 
prescription of psychotropic drugs, or experience of severe cardiovascular events [17] have 
all been associated with severely stressful life events, including natural disasters [18], war 
[19], and economy collapse [20]. 
Various biomarkers have been introduced to assess stress response. The physiological 
changes of stress system can be evaluated through measurement of bio-samples, including 
blood, saliva, urine, hair, and proxy autonomic markers [11]. Cortisol is commonly used as 
indicator for hypothalamic-pituitary-adrenal (HPA) axis activation. The elevated level of 
cortisol is a reflection of activated corticotropin-releasing hormone pathway, which can 
inhibit the HPA system via negative feedback to the hippocampus [21]. During ‘stress 
reactivity’, cortisol increases from baseline level following the onset of a stressor, and then 
returns to baseline level again at ‘stress recovery’ [21]. Similar with HPA-axis activation, the 
extent of change in the sympathetic-adrenal-medullary activation can also be assessed by 
biomarkers. For example, the levels of catecholamines, e.g. adrenaline and noradrenaline, 
secreted from adrenal glands are usually evaluated in blood and urine samples. Additionally, 
indirect effects of sympathetic-adrenal-medullary activation, e.g. vital signs, can be identified 
by the use of proxy autonomic measures [22], including blood pressure [23], heart rate 
variation [24], and respiratory rate [25]. 
Severe stress response to a cancer diagnosis 
Receiving a cancer diagnosis, independent of the cancer disease itself or cancer treatment, 
may serve as a severe psychological stress to cancer patients and lead to serious health 
consequences [26, 27]. Severe stress response after a cancer diagnosis may reflect low stress 
resilience, lack of social support, preexisting psychological problems, chronic stress 
exposure, etc., and may potentially alter cancer progression. Previous studies have shown 
increased risks for various health consequences following a cancer diagnosis, including 
posttraumatic stress disorder [16], depression [27, 28], other psychiatric disorders [29, 30], 
suicide [31, 32], and life-threatening cardiovascular events [15, 17, 33-35]. In a meta-analysis 
including 24 hospital-based studies of cancer patients, around one third of cancer patients 
were found to have a prevalent mental disorder [28].  
For cancer patients, the severe stress response may arise even before receiving the final 
diagnosis. We have shown in a recent study a rapid rise of mental disorders not only 
immediately after cancer diagnosis but also during the year before diagnosis [36]. The stress 
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response to a cancer diagnosis is therefore likely present at all stages of cancer course, during 
the diagnostic workup [37], while making treatment decision [38], as well as when 
experiencing treatment side effects [39], the increasing physical distress [40], disease 
recurrence and metastasis [41], and eventually the end of life issues [41]. 
1.2 Severe stress response, healthcare use, and cancer mortality 
The role of psychological factors on cancer progression has been an interesting research topic 
over the last decades. Data from animal studies, e.g. of ovarian and prostate cancers, suggest 
that behavioral stress may change the microenvironment of cancer cells, and subsequently 
promote tumor progression and shorten survival [42, 43]. In a murine breast cancer model, 
adverse social environment has been associated with the pathways that are known to increase 
breast cancer growth, including up-regulated lipid synthesis and gene expression of glycolytic 
pathway [44].  
Findings from human studies on the role of stress response on cancer survival are however 
inconclusive. In a meta-analysis of 165 prospective studies, stressful life experience or 
negative emotional response was shown to be associated with poorer cancer survival or 
greater cancer-specific mortality, especially among patients with lung, breast, and 
hematopoietic cancers [45]. Stress response to a breast cancer diagnosis, in terms of 
hopelessness and helplessness, was suggested to significantly reduce the disease-free survival 
in two studies [46, 47]. Similar factors were however not found to be associated with the 
length of breast cancer survival in other studies [48, 49].  
Findings from human studies on the role of mental disorders on cancer survival are in general 
less conflicting. Mental disorders are major contributors to the health burden of the general 
population, and the magnitude of such contribution is increasing [50]. Mental disorders have 
been associated with increased risk for many chronic illnesses, including coronary artery 
disease [51] and stroke [52], as well as disability-adjusted life-years [50]. Among cancer 
patients, mental disorders were shown to be associated with a higher risk of mortality as well 
as longer hospital stay [53]. Mental morbidities have also been associated with a shorter 
event-free cancer survival and shorter time to relapse [47]. In a population-based cohort 
study, prostate cancer patients with a recently diagnosed depression were shown to have 
worse overall survival, potentially due to compromised compliance to treatment [54]. Among 
non-small cell lung cancer patients, depression at baseline and shortly after cancer diagnosis 
was also shown to predict worse survival [55]. Similarly, increased risk for all-cause 
mortality was observed among colorectal and blood cancer patients with depressive 
symptoms [56]. Most of the literature so far has focused on depression, whereas the role of 
other stress-related mental disorders (e.g., stress reaction and adjustment disorder and 
anxiety) on cancer progression and healthcare use has rarely been assessed.    
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1.3 Beta-blocking agents and severe stress response to cancer diagnosis 
Randomized trials have found that beta-blocking agents can reduce occurrence of 
comorbidity, improve symptoms, and as a result lead to decreased mortality among patients 
with severe cardiovascular diseases, including heart failure [57, 58], cardiac arrest [59], and 
acute myocardial infarction [60]. The decreased mortality tended to be persistent across 
disease severity, and was noticed among patients with both mild to moderate [57, 61-63] and 
severe [58] heart failure. Cardiovascular events were commonly reported as a severe stress 
response among cancer patients [15, 17, 33, 36]. Pre-clinical studies have suggested that beta-
blocking agents inhibit the autonomic nerves system [64, 65], which is usually stimulated by 
psychological distress. Findings from observational studies have also associated beta-
blocking agents with reduced risk for overall mortality and cancer-specific mortality among 
cancer patients [66-68]. However, whether or not beta-blocking agents would reduce the risk 
of severe cardiovascular events directly after receiving a cancer diagnosis is not known. 
1.4 Psychological stress and stress response during the diagnostic workup 
of prostate cancer 
Prostate cancer diagnostic workup may be an important source of emotional stress [69]. High 
(50–64%) prevalence of anxiety has been reported in men investigated for and diagnosed 
with prostate cancer [70, 71]. Among patients evaluated for a suspected prostate cancer, 
prostate biopsy was found to be most stressful; around 20% of the men underwent prostate 
biopsy reported high psychological distress and tense or anxious mood [72]. One study used 
quantitative measurements of stress hormones throughout the prostate cancer diagnostic 
workup and found that the time period when waiting for a final cancer diagnosis was more 
stressful than the post-diagnosis period [37]. In a study investigating the level and prevalence 
of anxiety and depression among men undergoing diagnosis for prostate cancer, waiting for 
biopsy result was found to lead to the highest median Visual Analogue Scale score and the 
most stress [27]. In a study on the short-term effect of prostate cancer screening, anxiety level 
was found to be highest in men who had a biopsy, but not received a result yet [73]. 
Similarly, serum cortisol, as a bio-marker for psychological stress, was found to peak in the 
stage of waiting for biopsy result, among men that underwent prostate cancer screening [74]. 
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2 AIMS 
In this thesis, the overall aim was to investigate the severe stress response among cancer 
patients, especially around and after receiving cancer diagnosis. Using mental disorders as 
indicator of severe stress response to receiving a cancer diagnosis, we wanted to understand the 
role of stress response on the healthcare use pattern and cancer-specific mortality. We further 
aimed to explore the dynamic change of psychological stress experience during cancer 
diagnostic workup and assess the potential use of different interventions in preventing a severe 
stress response among cancer patients. 
The specific aims were: 
 To examine the role of mental disorders newly diagnosed after the cancer diagnosis, as 
an indicator of a severe stress response to the cancer diagnosis, on cancer-specific 
mortality. 
 To estimate the effect of mental disorders diagnosed immediately before or after a 
cancer diagnosis on the subsequent rate of hospital admissions for common 
comorbidities among cancer patients, including infections, injuries, and cardiovascular 
diseases. 
 To explore the association of beta-blocking agents used shortly before cancer diagnosis 
with the risk of severe cardiovascular events after cancer diagnosis.  
 To characterize and quantify the psychological stress experience and assess its 
association with waiting-time during diagnostic workup for prostatic cancer, from a 
randomized clinical trial. 
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3 STUDY MATERIALS 
3.1 Swedish population and health registers 
In Sweden, every resident is assigned a unique national registration number (NRN) at the time 
of birth or immigration, which is used in all national population and health registers [75]. Major 
events in an individual’s life are all recorded in these registers, such as birth, education, work, 
marriage, family relationships, medical records, immigration, and death. The unique NRN 
allows cross-linkages between these registers and subsequently individual follow-up of the 
entire nation. And prior to academic research, all the individual records were anonymized and 
de-identified. 
Cancer Register 
The Swedish Cancer Register was founded in 1958 and covers the entire population of Sweden. 
Healthcare providers, including clinicians and pathologists, are required by law to report all 
newly diagnosed cancer cases to the register [76]. This register includes mainly three types of 
information as following:  
1) Data on the patient, including the Swedish NRN, age at diagnosis, gender, and place of 
residence; 
2) Medical data, including cancer site, date of diagnosis, and histological type. From year 2004, 
information on cancer stage has also been collected; 
3) Follow-up data, including date of death, causes of death, and date of migration. 
Patient Register 
The Swedish Patient Register was founded in 1964/1965, and since 1987 it has national 
coverage for all discharge records from inpatient care visit in Sweden [77]. Each year, about 
1.5 million hospital discharge records are reported to this register. From 1997 and onward, 
surgical daycare procedures are also reported to the Patient Register, and since 2001, all 
counties in Sweden are obliged to report hospital-based outpatient specialist visits to the Patient 
Register. The register covers currently >80% of the entire country regarding outpatient visits. 
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Diagnoses in this register are coded according to the Swedish revisions of the International 
Classification of Diseases (ICD) codes, and from 1997 onward the 10th ICD codes have been 
used. The Patient Register is essential for population-based epidemiological research because it 
allows us to for example study the incidence and prevalence of different diseases, examine the 
effect and consequences of different interventions, and establish cohorts of patients with a 
certain disease or condition. 
Prescribed Drug Register 
The Swedish Prescribed Drug Register contains information on all dispensed drugs and covers 
the entire Swedish population, since July 2005. The register holds data on all dispensed drugs 
classified according to the Anatomical Therapeutic Chemical (ATC) System, including 
dispensing date, quantity, daily dose, and defined daily dose (DDD) of the prescribed drug [78]. 
Causes of Death Register 
The Swedish Causes of Death Register contains data from 1961 and is updated every year, 
including information on date as well as underlying and contributory causes of death [79]. The 
Causes of Death Register covers all deaths in Sweden, and the causes of death are coded 
according to ICD codes.  
Other registers 
Longitudinal Integration Database for Health Insurance and Labor Market Studies, as a part of 
Statistics Sweden's Business Register, has since 1990 annually updated information regarding 
labor market, and educational and social sectors for all individuals at age 16 onward in 
Sweden.  
Finally, the Total Population Register includes information about birth, marriage status, 
migration, and death for all residents of the country from 1968 [80]. For example, Migration 
Register is part of the Total Population Register and holds information on dates of migration 
that was used to determine the end of follow-up for different cohort studies included in the 
thesis.  
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3.2 Randomized clinical trial  
A randomized clinical trial based in the Urology Department at Örebro University Hospital was 
performed to include all men referred to the hospital for suspected prostate cancer. Eligible 
participants were men 85 years or younger, who were able to speak and write Swedish and did 
not show signs of advanced prostate cancer, or severe psychiatric or somatic diseases. 
Since October 2016, all eligible men have been invited to participate and those who accept are 
randomized to either a fast-track intervention or to a usual care control group. Until May 2018, 
204 men had participated in the study and were randomized. The fast-track diagnostic workup 
entails the possible shortest waiting-time: 1 week from randomization to the urologist visit 
(biopsy if needed), 1 week from biopsy to diagnosis, and 1 week from diagnosis to treatment 
decision. In the control group, the usual care involves waiting-times of approximately 1 week-3 
months, about 2 weeks, and 2 weeks, respectively, during these steps. Men in both arms are 
first assessed at the urology clinic for baseline characteristics directly after randomization, and 
then again before the urologist visit. The men will be further followed and assessed at time of 
diagnosis, 1 month after diagnosis, and two additional times during follow-up (6 and 12 months 
after urologist visit/biopsy). Written informed consent is obtained from all participants. The 
study was also registered in the trial database at Research and Development of Sweden (FoU 
Sweden, ID 207411).  
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4 STUDY DESIGN AND METHODS 
4.1 First-onset mental disorders and cancer-specific mortality 
Taking advantage of the Swedish national health registers, we performed a retrospectively 
defined cohort study including all cancer patients diagnosed during 2004-2009 in Sweden. 
Based on the Cancer Register, 244,261 adult cancer patients (≥ 30) were included after 
exclusion of diagnosis at autopsy and emigration before cancer diagnosis. We followed these 
patients from date of cancer diagnosis until death, emigration, or December 31, 2010 through 
cross-linkages to the Causes of Death Register and the Migration Register. 
Stress-related mental disorders, including mood-, anxiety- and substance abuse disorders, were 
used as the primary exposure, reflecting the severe stress response to cancer diagnosis. Cancer-
specific mortality identified from Causes of Death Register was used as the primary outcome. 
Cancer patients were deﬁned as having a cancer-speciﬁc death, if their cancer diagnosis and the 
underlying cause of death indicated the same site or group of cancer. 
4.1.1 Cancer site and stage 
Cancers were classified and grouped according to the 7th Swedish revision of the ICD codes, 
including facial cancer (140-148), digestive cancer (150-159), lung and thorax cancer (160-
165), bone cancer (196), skin cancer (190-191), soft tissue cancer (197), breast cancer (170), 
other female genital cancer (171-176), male genital cancer (177-179), urinary cancer (180-181), 
CNS and eye cancer (180-181), endocrine cancer (194-195), and hematologic cancer (200-
207).  
In the Cancer Register, the completeness of information on cancer stage at diagnosis has been 
high since 2004, and we used FIGO stage for gynecologic cancers (ICD-7: 171-176) and TNM 
for other cancers (except for hematological and CNS malignancies). Cancer stage was 
accordingly classified as localized cancer (T localized/N0/M0 or FIGO 0, I), local spread 
cancer (T advanced/N0/M0 or FIGO II), regional spread cancer (any T/N+/M0 or FIGO III), 
and advanced cancer (any T/any N/M+ or FIGO IV) [81]. The conventional values of T record 
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were assessed and assigned to the corresponding T-localized and T-advanced categories, for 
each specific cancer type separately (Table 1). 
Table 1. Conventional T values corresponding to T localized or T advanced. 
Cancer site T localized T advanced 
Lip/oral cavity, Pharynx, Larynx, Paranasal sinuses, Salivary 
glands, Oesophagus, Stomach, Small intestine, Colon/rectum, Anal 
canal, Liver, Gallbladder, Extrahepatic bile ducts/ampulla, 
Pancreas, Lung, Pleura, Vulva, Vagina, Cervix, Corpus, Penis, 
Prostate, Testis, Kidney, Pelvis/ureter, Bladder, Urethra, Sarcoma 
of orbit 
T1 – T2 T3 – T4 
Thyroid, Skin, Melanoma, Breast, Eye T1 – T3 T4 
Bone, Soft tissue, Ovary, Fallopian tube, Trophoblastic T1 T2 – T3 
4.1.2 Stress-related mental disorders 
Mental disorders were ascertained through the Patient Register. For all cancer patients, we 
identified the first mental disorder diagnosis (ICD10: F00-F99) after cancer diagnosis. The 
following mental disorders were included as stress-related mental disorders: mental and 
behavioral disorders due to psychoactive substance use (ICD10: F10-F16, F18-F19), 
depression (ICD10: F32-F33), stress reaction/adjustment disorder (ICD10: F43), anxiety 
(ICD10: F40-F41), and somatoform/conversion disorder (ICD10: F44-F45). These mental 
disorders (e.g. mood-, anxiety- adjustment- and substance abuse disorders) are commonly 
diagnosed among cancer patients [36, 82], with highly increased risks noticed immediately 
before and after cancer diagnosis [36], and are also potentially related to severe psychological 
stress [83, 84]. Other mental disorders (ICD10: F00-F99 excluding stress-related mental 
disorders mentioned above) were used as the secondary exposure. Exposure was used as time-
dependent variable, so cancer patients were classified as exposed from the date of their mental 
disorder diagnosis. We further divided the main exposure according to time since cancer 
diagnosis, e.g. a diagnosis of mental disorders within 90 days after cancer diagnosis or beyond 
90 days after cancer diagnosis. 
4.1.3 Cancer-specific mortality 
Underlying cause of death was identified by cross-linking the cohort to the Causes of Death 
Register. If the underlying cause of death for a cancer patient was the same cancer site or group 
as the cancer diagnosis, the patient was defined as having a cancer-specific death.  
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4.1.4 Statistical analysis 
We used Cox proportional hazards regression to assess the association of mental disorders after 
cancer diagnosis with cancer-specific mortality, yielding hazard ratios (HRs) with 95% 
confidence intervals (CIs).  
We calculated HRs of cancer-specific mortality for patients with mental disorders (stress-
related and others) after cancer diagnosis compared to patients without any mental disorders 
after cancer diagnosis. We further calculated HRs for patients with stress-related mental 
disorders diagnosed within 90 days after cancer diagnosis or beyond.  
To specifically explore the role of first-onset mental disorders (i.e. patients with a mental 
disorder diagnosed after cancer diagnosis but without a history of mental disorders before 
cancer diagnosis), separate analyses for patients with and without a history of mental disorders 
before cancer diagnosis were performed. History of mental disorders was obtained from 
January 1st 1987 until date of cancer diagnosis. We conducted the analysis first for all cancer 
types together, and then separately for the most common cancer sites or groups, including 
breast cancer, prostate cancer, colorectal cancer, lung cancer, renal or bladder cancer, 
melanoma, hematological malignancies, and severe cancers. We combined cancers of 
esophagus, liver, and pancreas into one group of severe cancers. 
We also calculated the HRs of cancer-specific mortality for specific stress-related mental 
disorders. Finally, we stratified the analysis by age at diagnosis, sex, calendar period of 
diagnosis, educational level, and cancer stage at diagnosis, to assess potential effect modifiers 
of the studied association. 
In all statistical analyses, age at follow-up was used as the underlying timescale and we 
adjusted for age at cancer diagnosis (as a continuous variable), sex, calendar period of 
diagnosis (2004-2006 and 2007-2009), educational level (≥9 years, <9 years), and disease stage 
at diagnosis. In the analysis for any cancer we further adjusted for cancer site or group, and in 
the analysis of hematological malignancies we further adjusted for cancer subtype (Hodgkin 
lymphoma, non-Hodgkin lymphoma, myeloma, and leukemia). 
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To test whether cancer patients exposed to mental disorders would receive different treatment 
compared to other cancer patients, leading to potentially different survival, we performed an 
additional analysis among patients with a cancer for which surgical treatment is commonly 
used as the primary treatment, including prostate, lung, and colorectal cancers. In this analysis, 
we ascertained records of surgical treatments, and compared the percentage of as well as the 
waiting-time for surgical treatments, among cancer patients exposed and unexposed to mental 
disorders after diagnosis.  
All the statistical analyses were carried out in SAS 9.4 (SAS Institute, North Carolina, United 
States) and Stata13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP). The study was approved by the Regional Ethical Review Board at the 
Karolinska Institutet, Stockholm, Sweden. 
4.2 Stress-related mental disorders around cancer diagnosis and hospital 
admission 
Based on the Swedish Cancer Register, we conducted a cohort study, including all adult 
patients (30 years and above) with a first primary cancer diagnosed between 2004 and 2009 in 
Sweden (N=251,214). Patients with cancer diagnosed at autopsy or emigrated before cancer 
diagnosis were not included. Because the occurrence of mental disorders might be 
physiologically related to the lesion of CNS [85, 86], patients with CNS tumors (N=6,061) 
were excluded.  
As indicator of a severe stress response toward the diagnostic process and the eventual 
diagnosis of cancer, stress-related mental disorders diagnosed from 90 days before to 90 days 
after cancer diagnosis were used as the primary exposure of interest, and other mental disorders 
diagnosed at the same time window were used as the secondary exposure. After further 
excluding cancer patients that died within 90 days after cancer diagnosis, we included 218,508 
patients in the analysis and followed them from 91st day after diagnosis until date of death, date 
of emigration, or December 31st 2010, whichever occurred first. During follow-up, we studied 
all kinds of hospital admissions as well as the three most common reasons for hospital 
admission including external injuries, infections, and cardiovascular diseases. 
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4.2.1 Hospital admission after cancer diagnosis 
We assessed hospital admissions by cross-linking the cancer patients to the Patient Register. 
The dates of admission and discharge were identified for each admission, and used to calculate 
the length of hospital stay. Consecutive hospital admissions between hospitals or departments 
were treated as one admission event. The main discharge diagnosis was retrieved and used as 
the reason of each hospitalization. The analysis was first performed for any hospital admission 
together after cancer diagnosis, as a proxy for overall impatient healthcare utilization. We then 
performed the analysis separately for the three types of common hospital admissions, including 
external injuries (ICD10: S00-S99, T00-T36, T51-T79, T89-T95, T97-T98.2, T98.4-T99) - 
both unintentional injuries (ICD10: V01-X59, Y85-Y86) and self-harm (ICD-10: X60-X84, 
Y870) [87], infections (ICD10: A00-A99, B00-B99), and cardiovascular diseases (ICD10: I00-
I99). The length of hospital stay could reflect the demand of healthcare, so we also performed 
the analysis for hospital admissions of different durations (<4 days, 4-10 days, and >10 days). 
4.2.2 Statistical analysis 
Cox proportional hazards regression was used to assess the association between mental 
disorders diagnosed from 90 days before to 90 days after a cancer diagnosis with the 
subsequent rate of hospital admissions. In the analysis, we also used a clustered sandwich 
estimator to account for intra-individual correlation, since cancer patients might be repeatedly 
admitted to hospital. The analysis was first performed for all cancer patients together, and then 
separately for patients with the most common cancer type, including breast cancer, prostate 
cancer, colorectal cancer, lung cancer, melanoma, kidney or bladder cancer, severe cancers, and 
hematological malignancies.  
In all statistical analyses, age at follow-up was used as the underlying timescale and we 
additionally adjusted for age at cancer diagnosis (as a continuous variable), sex, calendar year 
of cancer diagnosis (2004-2009), cancer type, cancer stage at diagnosis (except for 
hematological cancers), educational level (≥9 years or <9 years), and history of mental 
disorders (yes or no). History of mental disorders was ascertained from the Patient Register, 
assessing anytime from 2001 to 90 days before cancer diagnosis. In the analysis for 
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hematological cancers, we further adjusted for cancer subtype (Hodgkin lymphoma, non-
Hodgkin lymphoma, myeloma, and leukemia).  
To assess potential effect modifiers of the studied associations, we further stratified the 
analyses by age group (≤65, 66-75, and >75 years), sex, calendar period of diagnosis (2004-
2006, 2007-2009), educational level, history of mental disorders, and cancer stage at diagnosis.  
Cancer patients receiving a diagnosis of mental disorder around their cancer diagnosis could 
have different types of cancer treatment compared to other patients, which might lead to 
different hospital admission rates. For cancers that are commonly treated by surgery, including 
prostate, lung, or colorectal cancers, we performed a sensitivity analysis by further adjusting for 
surgery (yes or no).  
All the statistical analyses were performed using SAS 9.4 (SAS Institute, North Carolina, 
United States) and Stata15.1 (StataCorp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC). The study was approved by the Regional Ethical Review Board 
at the Karolinska Institutet, Stockholm, Sweden. 
4.3 Beta-blocking agents and severe cardiovascular events after cancer 
diagnosis 
We conducted a cohort study including all adult cancer patients (age at diagnosis ≥30) 
diagnosed from 2006 to 2013 in Sweden. After exclusion of diagnoses confirmed at autopsy 
(N=599), individuals that had ever emigrated out of Sweden before cancer diagnosis 
(N=12,808), and patients with hematological cancers and central nervous system tumors 
(N=33,029), our analytic cohort comprised 305,422 cancer patients.  
Cancer patients that used beta-blockers during the 90 days before cancer diagnosis, including 
the day of diagnosis, were classified as exposed. We followed cancer patients from date of 
diagnosis until emigration, death, or end of 2014, whichever occurred first. Severe 
cardiovascular events occurred during follow-up were our main outcome of interest, which was 
defined as a death with a cardiovascular disease as the underlying cause of death, or a hospital 
admission with a cardiovascular disease as the main discharge diagnosis. 
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4.3.1 Treatment of beta-blockers shortly before cancer diagnosis  
All dispenses of beta-blockers (ATC: C07AA, C07AB, C07AG, and C07FB) before cancer 
diagnosis were identified from the Swedish Prescribed Drug Register. Treatment period of 
beta-blockers was calculated from the most recent dispense and started from the dispensing 
date. According to information of the prescription, we estimated the duration of treatment from 
the division of total amount of dispensed drug by recommended daily dose. Multiple records 
for an identical beta-blocker at the same collection date were identified and summed up. Any 
record of unused beta-blockers that were returned to the pharmacies was also retrieved and the 
returned amount was detracted from total amount of the drug. In the study cohort, only cancer 
patients with a treatment period of beta-blockers that overlapped with the 90 days’ time-period 
before cancer diagnosis were classified as “exposed”. Patients with missing information on 
recommended daily dose from the Drug Register were excluded.  
Exposed to beta-blocker treatment was further classified according to recommended daily dose 
(high: recommended daily dose >0.5 defined daily dose, and low: recommended daily dose 
≤0.5 defined daily dose), receptor activity (non-selective [ATC: C07AA], selective [ATC: 
C07AB], alpha and beta blocking agents [ATC: C07AG], and combined tablets of beta-
blockers and calcium channel blockers [ATC: C07FB]), and time to cancer diagnosis (current 
use: treatment period covering the date of cancer diagnosis, and recent use: treatment period 
not covering the date of cancer diagnosis).  
4.3.2 Severe cardiovascular events after cancer diagnosis 
A hospital admission with a cardiovascular disease as the main discharge diagnosis (identified 
from the Patient Register; ICD-10: I00-I99), or death with a cardiovascular disease as the 
underlying cause of death (identified from the Causes of Death Register) were identified and 
defined as a “severe cardiovascular event”. The main outcome was then classified as fatal or 
non-fatal cardiovascular event. A hospital discharge for which cardiovascular disease was 
indicated as the main discharge record that was followed by a death due to a cardiovascular 
disease within 30 days after the discharge, and a death due to a cardiovascular disease that was 
not preceded by a related hospital admission were classified as fatal event. A hospital discharge 
for which cardiovascular disease was indicated as the main discharge record that did not lead to 
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a death within 30 days were classified as non-fatal event. The severe cardiovascular events 
were also classified by specific diagnoses, including myocardial infarction (ICD-10: I20-I25), 
hypertension or aortic rupture (ICD-10: I10-I13, I71, I72), stroke (ICD-10: I60-I64), embolism 
(ICD-10: I26, I74, I80-I82), and arrhythmia or heart failure (ICD-10: I44-I50). 
4.3.3 Ascertainment of comorbidity  
A high-dimensional propensity score (hd-PS) algorithm [88] was performed to select 
covariates. We identified all records of specialist-based healthcare use from the 365 days to 90 
days before cancer diagnosis for all cancer patients. We used 5 data dimensions, including 1) 
clinical diagnoses (ICD-10) and 2) medical procedures (Swedish Classification of care 
measures) from an outpatient specialist visit, 3) discharge diagnoses (ICD-10) and 4) medical 
procedures from an inpatient specialist visit, as well as 5) prescribed drugs (ATC), from either 
the Patient Register or the Prescribed Drug Register. We set the granularity to three digits for 
clinical diagnoses, medical procedures, and drugs. The first 100 most prevalent codes from 
each dimension were selected to candidate empirical covariates. Each code was assessed by 
how frequently it was recorded for each patient, and divided into three levels (once, sporadic, 
and frequent). We prioritized covariates across data dimensions by their potential for 
controlling for confounding that was not conditional on exposure and other covariates, leading 
to the top 500 covariates of all covariates (5*100*3) being included in the final hd-PS 
algorithm [88].  
We also introduced Chronic Disease Score [89, 90] to calculate the prescribed medication-
based comorbidity for each cancer patient. All prescribed drugs from 365 days to 90 days 
before cancer diagnosis were identified from the Prescribed Drug Register and the number of 
distinct prescribed drugs was used as the comorbidity measure; the potential range of values is 
0-35. Drugs that had the same first three digits of ATC codes were considered as the same 
class. 
4.3.4 Statistical analysis 
We used Cox proportional hazards regression to assess the association of beta-blocker 
treatment with the risk of severe cardiovascular events after cancer diagnosis. We mainly 
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focused on the first 90 days after cancer diagnosis. To estimate the temporal pattern of the 
association, we also performed the analysis during more than 90 days after cancer diagnosis. 
The analysis was first performed for any severe cardiovascular events, and then separately for 
fatal, non-fatal, and diagnosis-specific event. We also performed the analysis separately 
according to receptor selectivity, recommended daily dose, and recentness of use of beta-
blockers. We analyzed all cancer patients together first, and then separately patients with the 
most common cancer types, including breast cancer, prostate cancer, colorectal cancer, lung 
cancer, malignant melanoma, kidney or bladder cancer, and severe (esophageal, liver, and 
pancreatic) cancers.  
To assess potential effect modifiers of the associations, we further stratified the analyses by age 
at diagnosis (≤65, 66-75, and >75 years), sex, calendar period (2006-2007, 2008-2009, 2010-
2011, and 2012-2013), educational level (post-secondary school, secondary school, ≤9 years), 
cancer stage at diagnosis, Chronic Disease Score (0, 1-2, 3-5, and ≥6), beta-blocker history (yes 
or no), cardiovascular disease history (yes or no), and mental disorder history (yes or no). 
Patients that had at least one diagnosis of cardiovascular disease (ICD-10: I00-I99) or mental 
disorder (ICD-10: F00-F99) through inpatient or outpatient care, or that had dispensed beta-
blockers more than 90 days before cancer diagnosis were classified as having a history of 
cardiovascular disease, mental disorder, or beta-blocker use, respectively. The latest diagnosis 
for cardiovascular disease history was further classified according to ICD-10 codes as 
mentioned above. 
To assess whether the observed associations were specific to beta-blockers, we performed 
similar analysis for diuretics (ATC: C03), calcium channel blockers (ATC: C08), and agents 
acting on the renin-angiotensin system (ATC: C09), using the same 90 days before cancer 
diagnosis to classify exposure status. 
In all statistical models, we used calendar period of follow-up as the underlying timescale and 
additionally adjusted for age at diagnosis (as a continuous variable), sex, cancer type, cancer 
stage at diagnosis, educational level, beta-blocker history, cardiovascular disease history, 
mental disorder history, hd-PS, and other antihypertensive medicines (diuretics, calcium 
channel blockers, and agents acting on the renin-angiotensin system).  
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All the statistical analyses were performed using SAS9.4 (SAS Institute, North Carolina, 
United States) and Stata15.1 (StataCorp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC). The study was approved by the Regional Ethical Review Board 
at the Karolinska Institutet, Stockholm, Sweden.  
4.4 Fast-track clinical workup for men with suspected prostate cancer 
Based on the above-mentioned clinical trial, we randomized eligible participants referred to the 
Urology Department at Örebro University Hospital for suspected prostate cancer into 
intervention and control groups. In this study, we only presented baseline data at randomization 
and follow-up data at first urologist visit. Patients in the intervention group experienced a fast-
track workup where the shortest possible waiting-time was targeted, whereas the control group 
followed the usual care. From randomization to first urologist visit, we measured and compared 
the indications and symptoms of psychological stress, including self-reported symptoms of 
distress (anxiety, depression, distress, sleep disruption) and stress biomarkers (heart rate 
variability and diurnal cortisol level), between these two groups. 
4.4.1 Data collection  
Before randomization, the research nurses collected information on patients’ characteristics, 
including age, civil status (cohabitating or not), educational level (university or lower), living 
area (urban or rural), prostate specific antigen (PSA) level, comorbidity score (Charlson 
comorbidity index), and prostate symptom score. The prostate symptom score was assessed 
using the International Prostate Symptom Score (IPSS) and further evaluated in two aspects, 
including symptom score (score 0 to 35) and quality of life score (QOL, score 0 to 6) [91]. 
Different instruments, including questionnaire-based self-reported stress symptoms and 
measurements of stress biomarkers, were used to measure the stress experience at 
randomization and at first urologist visit. 
4.4.2 Questionnaires  
Before randomization, men were asked to complete the first questionnaire just after signing the 
informed consent when meeting with the research nurse. The second questionnaire was handed 
to the participants, so that they could complete it one day before their first urologist visit and 
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bring it back to the research nurse on the day of urologist visit. The combined 43-item 
questionnaire covers questions including indications and symptoms of psychological stress, 
anxiety, and depression. Specifically, we assessed levels of depression and anxiety with the 
Hospital Anxiety and Depression Scale (HADS) [92], self-evaluated distress with National 
Comprehensive Cancer Network (NCCN) distress thermometer [93], and sleep quality and 
disturbances through Åkerstedts Karolinska Sleep Questionnaire [94]. The HADS included 14 
items including seven items related to anxiety and another seven related to depression. Total 
scores for anxiety and depression were computed by summarizing scores of the contributing 
seven items respectively. In case of a missing item, we replaced it with the mean of the 
answered items in the subscale, if at least half of that subscale had been answered [95]. NCCN 
distress thermometer is a one-item visual-graphic measurement (range: 0 to 10), usually used to 
measure psychological distress in individuals with cancer. The sleep questionnaire includes 
seven items assessing the following three indexes during the week before measurement: the 
sleep quality index was the mean of four sleep items (difficulty in falling asleep, repeated 
awakening, premature awakening, and disturbed sleep), the sleep apnea index was the mean of 
two sleep items (cessation of breathing during sleep and snoring), and the self-rated sleep 
quality score (range: 1 to 5) was one-item measurement. For all measures, a higher value 
indicated a poor outcome. The men also reported in the same questionnaire smoking (never, 
former, and current, respectively for cigarette and snuff), previous treatment for psychiatric 
disorder (anxiolytics or antidepressants, yes or no), and social support by partner and others 
(high, moderate, and low).  
4.4.3 Saliva cortisol  
Saliva samples were collected the day before randomization and the day before the first 
urologist visit. Three samples were collected at each day, including at awakening in morning, 2 
pm, and 9 pm. The samples were stored according to the manufacturer’s instructions 
(Salimetrics). Saliva cortisol was measured using the High Sensitivity Salivary Cortisol 
Enzyme Immunoassay Kit according to the manufacturer´s instructions (Salimetrics, USA; 
Item No. 1-3002). The minimum detectable level of cortisol in the kit was 0.007 µg/dL, and the 
detection range was 0.012 - 3.000 µg/dL.  
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4.4.4 Heart rate variability 
Heart rate was measured using a handheld electrocardiogram (ECG) device (Zenicor-ECG® 
Medical systems, Zenicor Medical system AB, Stockholm, Sweden). Each patient was 
measured 3 x 30 second segments of ECG, when waiting for randomization and for first 
urologist visit. Heart rate was then analyzed to detect heart rate variation (HRV) for 
characterization of the individual’s stress profile.  
4.4.5 Statistical analysis 
Linear regression was performed on the three measures of cortisol levels within a day for each 
individual. The slope (‘β’) of the regression line predicting cortisol level from time of day was 
used to represent each participant’s cortisol diurnal rhythm [96]. The area under the curve 
(AUC) represented the total amount of secreted cortisol in the day. We also calculated two 
types of AUCs to provide different information about cortisol secretion: AUC with respect to 
ground (AUCG) and AUC with respect to increase (AUCI) [97]. 
The HRV was calculated as the degree of variation in the inter-beat intervals series (HRV =
Standard devison of QRS to QRS intervals series 
Mean of QRS to QRS intervals series 
× 100%) [98]. In addition, we also calculated the 
standard deviation of all normal to normal intervals (SDRR) for each ECG records, which is 
the most commonly used time domain measure of heart rate variability [99]. 
We compared the baseline characteristics between groups with t-test and Wilcoxon rank sum 
tests for continuous variables, and Chi-square test and Fisher’s exact test for categorical 
variables. Due to the small number of men with symptoms for anxiety and depression above 
the defined cut-off values, these variables were analyzed as an ordinary score. To normalize 
data, measures of distress, anxiety, depression, sleep quality, and sleep apnea were square root 
transformed, whereas HRV and SDRR were natural log transformed prior to statistical analysis. 
To evaluate the effect of the intervention, group differences in change over time between 
randomization and the urologist visit were compared as differences in percent changes. 
Generalized linear model was then used to compare the changes over time between the 
intervention and the control groups. The analysis was first conducted without adjustment and 
  21 
then adjusted for age, PSA level (log- transformed), Charlson comorbidity score, educational 
level, cohabitating status, living area, cigarette smoking, and snuff use.  
All tests are two-sided and an alpha level of 0.05 was applied to assess statistical significance. 
All the statistical analyses were performed using SAS9.4 (SAS Institute, North Carolina, 
United States). This study was approved by the ethics committee at Örebro University Hospital.   
 22 
5 RESULTS 
5.1 First-onset mental disorders and cancer-specific mortality 
After cancer diagnosis, 11,457 patients experienced a stress-related mental disorder, of which 
7,236 were first-onset, and 10,688 patients were diagnosed with other mental disorders, of 
which 6,661 were first-onset (Table 2).   
Compared to unexposed patients, patients diagnosed with stress-related mental disorders after 
cancer diagnosis had a 53% increased rate of cancer-specific mortality (Table 2). Stronger 
association was noted among patients with first-onset mental disorders after cancer diagnosis. 
Patients that experienced a recurrent mental disorder had only slightly elevated cancer-specific 
mortality. The increased cancer-specific mortality was observed for stress-related mental 
disorders both within and beyond 90 days after cancer diagnosis (Table 2). Cancer patients 
diagnosed with other mental disorders after cancer diagnosis also had increased cancer-specific 
mortality (62%, Table 2). The association was also stronger for first-onset, compared to 
recurrent, mental disorders (Table 2). 
Table 2. Association of mental disorders with cancer-specific mortality, shown by time 
since cancer diagnosis 
 
Entire follow-up 
90 days after cancer 
diagnosis 
>90 days after cancer 
diagnosis 
 N HR (95% CI)1 N HR (95% CI) N HR (95% CI) 
 Stress-related mental disorders 
Overall 11,457 1.53 (1.46 - 1.60) 3,232 1.30 (1.21 - 1.40) 9,314 1.68 (1.58 - 1.78) 
History of mental disorders 
No 7,236 1.82 (1.71 - 1.92) 1,313 1.52 (1.37 - 1.69) 5,923 1.97 (1.84 - 2.11) 
Yes 4,221 1.14 (1.05 - 1.24) 1,672 1.10 (0.98 - 1.22) 2,549 1.22 (1.08 - 1.38) 
 Other mental disorders 
Overall 10,688 1.62 (1.55 - 1.70) 2,936 1.44 (1.35 - 1.54) 7,752 1.73 (1.63 - 1.84) 
History of mental disorders 
No 6,661 1.85 (1.74 - 1.97) 1,060 1.65 (1.49 - 1.84) 5,601 1.96 (1.82 - 2.12) 
Yes 4,027 1.36 (1.26 - 1.47) 1,876 1.30 (1.18 - 1.43) 2,151 1.45 (1.29 - 1.64) 
1 HR: Hazard ratio; CI: Confident interval. 
In the analysis of specific cancers, an increased cancer-specific mortality by first-onset stress-
related mental disorders was observed among all the common cancer types. In contrast, no 
association was noted for recurrent mental disorders in any cancer type (Table 3). 
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Table 3. Association of stress-related mental disorders after cancer diagnosis with cancer-
specific mortality (HR, 95% CI)1 among patients with different cancer types 
Cancer site/group Overall 
No history of mental 
disorders 
History of mental 
disorders 
   Prostate cancer 1.84 (1.59 - 2.14) 2.42 (2.04 - 2.88) 1.23 (0.92 - 1.66) 
   Breast cancer  1.32 (1.10 - 1.57) 1.54 (1.26 - 1.89) 1.05 (0.73 - 1.50) 
   Lung cancer 1.42 (1.28 - 1.57) 1.68 (1.48 - 1.90) 1.14 (0.96 - 1.35) 
   Colorectal cancer 1.35 (1.20 - 1.53) 1.54 (1.33 - 1.79) 1.14 (0.91 - 1.42) 
   Melanoma 1.71 (1.23 - 2.37) 2.38 (1.66 - 3.42) 0.62 (0.25 - 1.56) 
   Hematological malignance 1.63 (1.40 - 1.91) 1.84 (1.54 - 2.20) 1.22 (0.89 - 1.67) 
   Renal/Bladder cancer 1.86 (1.55 - 2.24) 2.43 (1.95 - 3.02) 1.38 (0.98 - 1.93) 
   Severe cancers  1.19 (1.02 - 1.39) 1.30 (1.07 - 1.58) 1.34 (0.99 - 1.81) 
1 HR: Hazard ratio; CI: Confident interval. 
In the stratified analysis, the excess cancer-specific mortality by first-onset stress-related 
mental disorders after cancer diagnosis did not appear to differ largely between men and 
women; neither did it differ by age, calendar period of diagnosis, or educational level (Table 4). 
However, the increased mortality was stronger among patients with a diagnosis of lower stage 
cancer compared to patients with more advanced stage disease.  
Table 4. Association of first-onset and recurrent stress-related mental disorders after cancer 
diagnosis with cancer-specific mortality, stratified analyses 
 First-onset mental disorders Recurrent mental disorders 
 
N (%) HR (95% CI)1 N (%) HR (95% CI) 
Sex         
  Male 3,082 (42.59) 1.93 (1.77 - 2.10) 2,103 (49.82) 1.20 (1.07 - 1.34) 
  Female 4,154 (57.41) 1.71 (1.58 - 1.85) 2,118 (50.18) 1.10 (0.97 - 1.24) 
Age at follow-up, years 
 
   
   ≤65 3,906 (53.98) 1.73 (1.59 - 1.89) 2,575 (61.00) 1.23 (1.10 - 1.38) 
   66-75 1,785 (24.67) 1.99 (1.78 - 2.21) 969 (22.96) 1.12 (0.95 - 1.31) 
   >75 1,545 (21.35) 1.77 (1.59 - 1.98) 677 (16.04) 0.98 (0.81 - 1.18) 
Calendar period at diagnosis 
  2004-2006 4,310 (59.56) 1.78 (1.65 - 1.91) 2,049 (48.54) 1.11 (0.98 - 1.25) 
  2007-2009 2,926 (40.44) 1.89 (1.72 - 2.07) 2,172 (51.46) 1.19 (1.05 - 1.34) 
Educational level 
 
   
   >9 years 4,705 (65.02) 1.75 (1.62 - 1.88) 2,603 (61.67) 1.12 (0.99 - 1.25) 
   ≤9 years 2,515 (34.76) 1.88 (1.72 - 2.06) 1,611 (38.17) 1.13 (1.00 - 1.29) 
Cancer stage2 
 
   
   Localized   3,020 (41.74) 2.00 (1.73 - 2.31) 1,778 (42.12) 1.16 (0.91 - 1.46) 
   Local spread  826 (11.42) 2.04 (1.75 - 2.37) 512 (12.13) 1.35 (1.06 - 1.70) 
   Regional spread 1,041 (14.39) 1.85 (1.65 - 2.07) 562 (13.31) 1.29 (1.08 - 1.55) 
   Advanced 471 (6.51) 1.49 (1.32 - 1.69) 262 (6.21) 1.11 (0.92 - 1.35) 
   Unknown 1,139 (15.74) 1.65 (1.43 - 1.90) 710 (16.82) 1.11 (0.90 - 1.37) 
1 HR: Hazard ratio; CI: Confident interval. 
2 Patients with missing or unclear information of TNM/FIGO were classified as ‘Unknown’. 
Almost all subtypes (depression, anxiety, stress reaction and adjustment disorder, and mental 
and behavioral disorders due to psychoactive substance use) of first-onset stress-related mental 
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disorders were associated with an increased cancer-specific mortality, except 
somatoform/conversion disorder (Table 5).  
Table 5. Association of specific diagnosis of stress-related mental disorders after cancer 
diagnosis with cancer-specific mortality. 
 First-onset mental disorders1 Recurrent mental disorders 
 N (%)3 HR (95% CI)2 N (%) HR (95% CI) 
   Stress reaction 832 (11.50) 1.78 (1.51 - 2.11) 283 (6.70) 1.02 (0.73 - 1.42) 
   Depression 3109 (42.97) 1.76 (1.62 - 1.92) 1720 (40.75) 1.02 (0.89 - 1.16) 
   Anxiety 2061 (28.48) 2.11 (1.92 - 2.33) 959 (22.72) 1.27 (1.08 - 1.49) 
   Substance abuse  926 (12.80) 1.50 (1.25 - 1.79) 1212 (28.71) 1.29 (1.12 - 1.49) 
   Somatoform/conversion 
disorder 
308 (4.26) 1.20 (0.82 - 1.76) 47 (1.11) 1.36 (0.64 - 2.92) 
1 Patients without any mental disorders (ICD10: F00-F99) before cancer diagnosis. 
2 HR: Hazard ratio; CI: Confident interval. 
Prostate cancer patients with a first-onset stress-related mental disorder post diagnosis had 
similar percentage of surgery (p>0.05) compared to the unexposed patients; lung and colorectal 
cancer patients with first-onset mental disorders were on the other hand slightly more likely to 
have surgery (p<0.05) compared to the unexposed patients. Among patients with surgery, all 
prostate, lung, and colorectal patients with exposure to first-onset mental disorder had similar 
waiting-time from diagnosis to surgery compared to the unexposed patients (p>0.05) (Table 6). 
Adding surgery into the survival analysis did not alter our results greatly: HR=2.44 (95%CI: 
2.05-2.90) for prostate cancer; HR=1.67 (95%CI: 1.47-1.90) for lung cancer; and HR=1.55 
(95%CI: 1.34-1.79) for colorectal cancer. 
Table 6. Proportion of and waiting-time for surgical treatment by first-onset stress-related 
mental disorders after cancer diagnosis, analyses of patients with prostate, lung, or colorectal 
cancers 
 
No mental disorders 
First-onset stress-related 
mental disorders  
Prostate cancer 
Surgery1, (N, %)   p=0.19 
No 32,580 (73.05) 883 (74.77)  
Yes 12,019 (26.95) 298 (25.23)  
Waiting-time, days (mean, SD)2 171.10 (189.87) 155.20 (163.22) p=0.15 
Lung cancer 
Surgery3, (N, %)   p<0.01 
No 12,145 (89.06) 343 (80.52)  
Yes 1,492 (10.94) 83 (19.48)  
Waiting-time, days (mean, SD) 99.79 (103.73) 112.59 (155.42) p=0.29 
Colorectal cancer 
Surgery4, (N, %)   p<0.05 
No 17,507 (73.71) 542 (68.78)  
Yes 6,245 (26.29) 246 (31.22)  
Waiting-time, days (mean, SD) 55.90 (138.43) 62.79 (168.37) p=0.45 
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1 According to Swedish Classification of care measures (KVA), prostatectomy was included as the surgical 
treatment for prostate cancer (KVA: KEC00, KEC01, KEC10, KEC20). 
2 SD: Standard division. 
3 According to Swedish Classification of care measures (KVA), following surgical treatments for lung cancer 
were included: lung resection (KVA: GDB10, GDB11, GDB20, GDB21), lobectomy of lung (KVA: GDC00-
GDC97), and pulmonectomy (KVA: GDD00-GDD97). 
4 According to Swedish Classification of care measures (KVA), following surgical treatments for colorectal 
cancer were included: resection of right-sided semicolon (KVA: JFB30, JFB31), transverse colon (KVA: JFB40, 
JFB41), left semicolon (KVA: JFB43, JFB44), sigmoid colon (KVA: JFB46, JFB47), other part of colon (KVA: 
JFB50, JFB51), and colon with rectum (KVA: JFB53, JFB54, JFB60, JFB61, JFB63, JFB64). 
5.2 Stress-related mental disorders around cancer diagnosis and hospital 
admission after cancer diagnosis 
A total of 4,105 patients (1.88%) had a diagnosis of stress-related mental disorders and 3,594 
(1.64%) had a diagnosis of other mental disorders, during 90 days before to 90 days after 
cancer diagnosis. 
Compared to the cancer patients without any mental disorder during 90 days before to 90 days 
after cancer diagnosis, patients exposed to stress-related mental disorders experienced 35% 
increased rate of any hospital admission; whereas patients with other mental disorders had 7% 
increased rate (Table 7). Both associations were more pronounced for hospitalizations of long 
duration (>10 days). Among the three common hospital admissions, the strongest association 
by stress-related mental disorders was noticed for hospitalizations due to external injuries 
(unintentional injuries HR=1.85, 95%CI: 1.62 - 2.12; intentional injuries HR=6.64, 95%CI: 
1.09 - 40.31), followed by infections, and cardiovascular diseases. For other mental disorders, 
an increased rate was only noted for external injury- and infection-related hospitalizations.   
Table 7. Associations of mental disorders with rate of hospital admission  
 
Stress-related mental disorders; 
HR (95% CI)1 
Other mental disorders; 
HR (95% CI) 
Any hospital admission 1.35 (1.28 - 1.41) 1.07 (1.01 - 1.13) 
Main discharge diagnosis   
Injury 1.89 (1.67 - 2.14) 1.36 (1.20 - 1.55) 
Infection  1.28 (1.08 - 1.52) 1.19 (1.00 - 1.42) 
Cardiovascular disease 1.16 (1.03 - 1.30) 0.91 (0.80 - 1.03) 
Duration of admission 
  
   <4 days 1.25 (1.18 - 1.33) 1.01 (0.93 - 1.10) 
   4-10 days 1.32 (1.25 - 1.40) 1.04 (0.98 - 1.10) 
   >10 days 1.63 (1.53 - 1.73) 1.24 (1.15 - 1.33) 
1 HR: Hazard ratio; CI: Confident interval. 
A diagnosis of stress-related mental disorders around cancer diagnosis was associated with an 
increased rate of hospital admission among almost all cancer patients except for patients with 
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melanoma and severe cancers (Figure 1). Increased rate of hospital admission due to external 
injuries was found among almost all cancer patients except for patients with lung, melanoma 
and severe cancers. Among patients of breast, colorectal, and hematological cancers, an 
increased rate of hospital admission for infections was observed, whereas only patients with 
colorectal cancer was noted to have an increased rate of hospital admission for cardiovascular 
diseases. 
 
Cancer patients with a diagnosis of stress-related mental disorders around cancer diagnosis had 
on average a greater number of hospital admissions during follow-up (mean: 2.83; standard 
deviation: 3.91) compared to patients with other mental disorders (mean: 2.01; SD: 2.85). In the 
stratified analysis, we found similar results for all patients, regardless of sex, age, calendar 
period, educational level, previous mental disorders, or cancer stage (Table 8). 
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Figure 1. Associations of stress-related mental disorders with hospital admission, by cancer types
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Table 8. Median times of hospital admission, and associations of stress-related mental disorders 
with rate of hospital admission, stratified analyses. 
 No mental disorders  Stress-related mental disorders 
 
Median times of 
hospital admission 
(interquartile range)  
 
Median times of 
hospital admission 
(interquartile range)  
HR (95% CI)1 
Sex     
  Male 1 (0-3)  2 (1-4) 1.42 (1.32 - 1.52) 
  Female 1 (0-3)  1 (0-4) 1.28 (1.20 - 1.37) 
Age at diagnosis, years     
   ≤65 1 (0-2)  2 (0-4) 1.36 (1.27 - 1.45) 
   66-75 1 (0-3)  2 (1-4) 1.36 (1.25 - 1.49) 
   >75 1 (0-3)  2 (0-3) 1.21 (1.11 - 1.31) 
Calendar period at diagnosis     
  2004-2006 2 (0-3)  2 (1-4) 1.34 (1.25 - 1.44) 
  2007-2009 1 (0-2)  1 (0-3) 1.36 (1.28 - 1.45) 
Educational level      
   >9 years 1 (0-3)  2 (0-4) 1.34 (1.26 - 1.43) 
   ≤9 years 1 (0-3)  2 (0-4) 1.36 (1.27 - 1.46) 
Previous mental disorders      
   No 1 (0-3)  1 (0-3) 1.32 (1.24 - 1.41) 
   Yes 1 (0-3)  2 (1-4) 1.34 (1.25 - 1.43) 
Previous cardiovascular 
diseases  
 
   
   No 1 (0-3)  2 (0-4) 1.35 (1.28 - 1.43) 
   Yes 1 (0-3)  2 (1-4) 1.38 (1.27 - 1.50) 
Cancer stage2      
   Localized   1 (0-2)  1 (0-3) 1.48 (1.37 - 1.60) 
   Local spread  1 (0-3)  2 (0-4) 1.27 (1.12 - 1.43) 
   Regional spread 2 (1-3)  2 (1-4) 1.23 (1.12 - 1.37) 
   Advanced 2 (1-3)  2 (1-4) 1.08 (0.95 - 1.22) 
   Unknown 1 (0-3)  2 (0-4) 1.42 (1.27 - 1.60) 
1 HR: Hazard ratio; CI: Confident interval. 
2 Patients with missing or unclear information of TNM/FIGO were classified as ‘Unknown’. 
In the additional analysis further adjusting for surgery, we found similar increased rate of 
hospital admission by stress-related mental disorders among patients with prostate cancer 
(HR=1.56, 95%CI: 1.39-1.75), lung cancer (HR=1.32, 95%CI: 1.15-1.51), and colorectal 
cancer (HR=1.46, 95%CI: 1.27-1.69).  
5.3 Beta-blocking agents and severe cardiovascular events after cancer 
diagnosis 
During the 90 days before cancer diagnosis, 64,072 patients used beta-blockers. Cancer patients 
treated with beta-blockers tended to be older, have lower educational level, and have more 
comorbidities, compared to patients without beta-blockers (Table 9).  
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Table 9. Association of beta-blocker use during the 90 days before cancer diagnosis with 
the risk of severe cardiovascular events during the 90 days after cancer diagnosis  
 
Unexposed 
(N=341,350), % 
Exposed1 
(N=64,072), % 
HR (95%CI)2 
Sex      
  Male 51.70 56.47 1.15 (1.05-1.26) 
  Female 48.30 43.53 1.25 (1.12-1.40) 
Age at diagnosis, years 
  
 
   ≤65 45.64 23.74 1.40 (1.17-1.68) 
   66-75 29.27 35.69 1.24 (1.09-1.41) 
   >75 25.10 40.57 1.12 (1.02-1.23) 
Calendar period at diagnosis 
  
 
  2006-2007 23.82 23.20 1.21 (1.04-1.40) 
  2008-2009 24.66 24.77 1.13 (0.98-1.30) 
  2010-2011 25.66 25.28 1.13 (0.98-1.30) 
  2012-2013 25.87 26.75 1.01 (0.84-1.21) 
Educational level 
  
 
   Post-secondary school 24.75 17.04 1.01 (0.84-1.21) 
   Secondary school 39.92 37.48 1.28 (1.13-1.44) 
   ≤9 years 34.16 44.48 1.22 (1.10-1.35) 
  Missing 1.17 1.00 NA 
Cancer stage3 
  
 
   Localized   51.23 48.32 1.12 (0.99-1.26) 
   Local spread  12.27 14.30 1.24 (1.03-1.49) 
   Regional spread 11.86 11.08 1.24 (1.03-1.50) 
   Advanced 11.26 12.42 1.20 (1.00-1.43) 
   Unknown 13.39 13.88 1.23 (1.04-1.46) 
Chronic Disease Score 
  
 
   0 34.20 2.05 2.26 (1.74-2.93) 
   1-2 36.12 26.44 1.39 (1.17-1.63) 
   3-5 24.44 54.60 1.10 (1.00-1.21) 
   ≥6 5.24 16.91 1.11 (0.96-1.28) 
History of beta-blocking agents   
   No 86.48 5.52 2.49 (2.18-2.84) 
   Yes 13.52 94.48 0.98 (0.91-1.06) 
History of cardiovascular diseases   
   No 71.63 31.71 1.44 (1.24-1.67) 
   Yes 28.37 68.29 1.13 (1.04-1.22) 
History of mental disorders   
   No 78.86 80.60 1.19 (1.11-1.29) 
   Yes 21.14 19.40 1.16 (0.93-1.45) 
1 Cancer patients with a treatment period of beta-blockers that overlapped with the 90 days’ time-period before 
cancer diagnosis. 
2 HR: Hazard ratio; CI: Confident interval. 
3 Patients with missing or unclear information of TNM/FIGO were classified as ‘Unknown’. 
A stronger association was found between beta-blocker use during the 90 days before cancer 
diagnosis and severe cardiovascular events during the 90 days after cancer diagnosis, among 
patients with low chronic disease score, and patients without a history of beta-blocker use or 
cardiovascular disease (Table 9). Sex, age, calendar period, educational level, cancer stage, and 
history of mental disorders were not found to greatly modify the association. 
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Overall, cancer patients exposed to beta-blocker treatment during the 90 days before cancer 
diagnosis experienced 19% increased rate of severe cardiovascular events, compared to patients 
without such exposure (Table 10). The association was mainly attributable to non-fatal event, 
and was null for fatal event. In the analysis for specific diagnosis of severe cardiovascular 
events, patients with beta-blockers only had an increased rate for myocardial infarction, but not 
for other events. From 90 days after cancer diagnosis onward, a null result was noticed for the 
association between beta-blocker treatment and severe cardiovascular event, either overall or 
for fatal, non-fatal, or specific event separately (Table 10).  
Table 10. Association of beta-blockers used during the 90 days before cancer diagnosis 
with the risk of severe cardiovascular events after cancer diagnosis, a population-based 
cohort study in Sweden 2006-2013 
 Overall 
0-90 days after 
cancer diagnosis 
>90 days after 
cancer diagnosis 
Severe cardiovascular events 1.03 (1.00-1.06) 1.19 (1.11-1.28) 1.00 (0.97-1.03) 
Fatal or non-fatal events    
Fatal 0.97 (0.91-1.02) 1.08 (0.92-1.29) 0.95 (0.90-1.01) 
Non-fatal 1.04 (1.01-1.07) 1.21 (1.12-1.31) 1.01 (0.98-1.05) 
Specific diagnosis    
Myocardial infarction 1.00 (0.95-1.05) 1.22 (1.07-1.40) 0.97 (0.92-1.03) 
Hypertension / aortic rupture 1.00 (0.90-1.11) 1.21 (0.88-1.67) 0.98 (0.88-1.09) 
Stroke 0.98 (0.92-1.05) 1.02 (0.84-1.23) 0.98 (0.91-1.05) 
Embolism 0.92 (0.85-1.00) 1.01 (0.84-1.22) 0.91 (0.83-1.00) 
Heart failure / Arrhythmia 0.97 (0.91-1.03) 1.15 (0.96-1.37) 0.95 (0.89-1.01) 
During the 90 days after cancer diagnosis, no increased rate of fatal events was noticed in 
relation to beta-blocker use during the 90 days before cancer diagnosis for any specific cancer. 
A positive association was noted between beta-blocker use and non-fatal cardiovascular events 
during the 90 days after cancer diagnosis among patients with lung cancer, colorectal cancer, 
and melanoma. Beyond 90 days after cancer diagnosis, no association was found for fatal or 
non-fatal event (Table 11). 
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Table 11. Association of beta-blockers used during the 90 days before cancer diagnosis with the 
risk of severe cardiovascular events after cancer diagnosis, by cancer type 
 
Within 90 days after cancer diagnosis  Beyond 90 days after cancer diagnosis 
 Fatal events Non-fatal events  Fatal events Non-fatal events 
Cancer type      
Prostate cancer 1.46 (0.86-2.47) 1.07 (0.87-1.30)  0.97 (0.86-1.09) 1.00 (0.93-1.07) 
Breast cancer 1.69 (0.78-3.63) 1.29 (0.94-1.76)  0.89 (0.74-1.07) 1.05 (0.95-1.17) 
Lung cancer 1.47 (0.93-2.31) 1.37 (1.10-1.71)  1.01 (0.76-1.34) 1.12 (0.97-1.31) 
Colorectal caner 0.80 (0.52-1.23) 1.35 (1.11-1.64)  0.89 (0.76-1.04) 0.92 (0.84-1.01) 
Melanoma 2.60 (0.78-8.72) 1.72 (1.01-2.95)  0.95 (0.72-1.26) 1.04 (0.88-1.24) 
Urinary/Bladder 
cancer 
1.20 (0.71-2.03) 1.07 (0.84-1.36) 
 
0.95 (0.80-1.13) 1.00 (0.89-1.11) 
Severe cancers 0.71 (0.33-1.50) 0.74 (0.48-1.13)  0.71 (0.41-1.23) 1.24 (0.89-1.74) 
No statistically significant association was found between beta-blockers and fatal 
cardiovascular events during the 90 days after cancer diagnosis, regardless of receptor activity, 
recommended daily dose, and recentness of use to cancer diagnosis (Table 12). Beyond 90 days 
after cancer diagnosis, a lower rate of fatal events was noted for the use of both non-selective 
and selective beta-blockers. Beta-blockers with low daily dose were also associated with a 
slightly decreased rate of fatal events more than 90 days after cancer diagnosis. 
Table 12. Association of beta-blockers used during the 90 days before cancer diagnosis with the 
risk of severe cardiovascular events after cancer diagnosis, by subgroup of beta-blockers. 
 
Within 90 days after cancer diagnosis  Beyond 90 days after cancer diagnosis 
 Fatal events Non-fatal events  Fatal events Non-fatal events 
Receptor activity      
Non-selective 0.74 (0.47-1.17) 1.06 (0.88-1.27)  0.86 (0.76-0.98) 1.12 (1.04-1.20) 
Selective 1.07 (0.90-1.28) 1.21 (1.11-1.31)  0.91 (0.86-0.97) 1.00 (0.96-1.03) 
Alpha and Beta 1.56 (0.92-2.64) 1.59 (1.23-2.06)  1.86 (1.55-2.22) 1.18 (1.04-1.33) 
Combination with 
calcium channel 
blockers 
1.20 (0.53-2.73) 0.97 (0.61-1.53) 
 
1.12 (0.83-1.51) 1.00 (0.84-1.18) 
Recommended 
daily dose   
 
 
 
High 1.16 (0.96-1.40) 1.25 (1.15-1.37)  1.03 (0.96-1.09) 1.05 (1.01-1.09) 
Low 1.00 (0.82-1.22) 1.16 (1.06-1.28)  0.87 (0.82-0.93) 0.98 (0.94-1.02) 
Recentness of use 
to cancer diagnosis   
 
 
 
Current 1.07 (0.90-1.27) 1.20 (1.11-1.30)  0.95 (0.90-1.01) 1.01 (0.98-1.05) 
Recent 1.60 (0.89-2.86) 1.68 (1.27-2.22)  1.15 (0.91-1.46) 1.09 (0.94-1.27) 
Increased rate for severe cardiovascular events both within the 90 days after cancer diagnosis 
and thereafter was noticed by use of diuretics and agents acting on the renin-angiotensin 
system, but not calcium channel blockers, during the 90 days before cancer diagnosis (Table 
13). A slightly decreased rate of fatal events was found for calcium channel blockers during the 
entire follow-up (HR: 0.92, 95%CI: 0.88-0.97). 
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Table 13. Association of other antihypertensive drugs used during the 90 days before 
cancer diagnosis with the risk of severe cardiovascular events after cancer diagnosis, by 
time since cancer diagnosis 
 All events1 
Fatal or non-fatal events 
 Fatal Non-fatal 
Diuretics2    
Overall  1.21 (1.19-1.24) 1.39 (1.33-1.44) 1.20 (1.18-1.23) 
0-90 days  1.33 (1.27-1.41) 1.30 (1.14-1.47) 1.35 (1.27-1.43) 
>90 days 1.19 (1.16-1.22) 1.39 (1.34-1.45) 1.18 (1.15-1.22) 
Calcium channel blockers3   
Overall  1.03 (1.00-1.05) 0.92 (0.88-0.97) 1.06 (1.03-1.08) 
0-90 days 1.00 (0.94-1.06) 0.88 (0.76-1.03) 1.03 (0.96-1.10) 
>90 days 1.03 (1.00-1.06) 0.93 (0.89-0.98) 1.06 (1.03-1.09) 
Agents acting on the renin-angiotensin system4 
Overall  1.13 (1.11-1.16) 1.08 (1.04-1.12) 1.17 (1.14-1.20) 
0-90 days 1.14 (1.08-1.20) 1.10 (0.97-1.24) 1.18 (1.11-1.25) 
>90 days 1.12 (1.10-1.15) 1.08 (1.04-1.12) 1.16 (1.13-1.19) 
1 Severe cardiovascular events, including death due to cardiovascular diseases and hospital admissions with 
cardiovascular diseases as the primary discharge diagnosis. 
2 Diuretics (ATC: C03). 
3 Calcium channel blockers (ATC: C08). 
4 Agents acting on the renin-angiotensin system (ATC: C09). 
5.4 Fast-track clinical workup for men with suspected prostate cancer 
Among 206 men who came to the Urology Department at Örebro University Hospital with 
suspected prostate cancer, 204 were eligible and randomized. One man in the intervention 
group and three men in the control group dropped out between the two visits. A total of 102 of 
the 104 patients in the intervention group and 97 of the 100 patients in the control group 
answered questionnaires at randomization. A total of 98 of the 103 and 88 of the 97 patients in 
the two groups returned questionnaires at the urologist visit. Saliva samples were collected for 
87.5% and 88.0% of the patients at randomization, and 87.4% and 86.6% at urologist visit, 
from the intervention and control groups, respectively. Almost all men were measured for ECG 
at randomization (99.0% in the intervention group and 96.0% in the control group), and 88.3% 
and 84.5% at urologist visit (Figure 2). The present study focused on patients who returned 
questionnaires at both randomization and first urologist visit, including 97 patients from the 
intervention group and 88 patients from the control group (Figure 2). 
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Men in the fast-track group experienced a shorter waiting-time to the urologist visit (mean=11 
days) than men in the usual care group (mean=51 days, p for difference <0.01, Table 14). 
Patients of the intervention and control groups had similar characteristics, including age, 
pension rate, PSA level, IPSS score, Charlson comorbidity index, educational level, living area, 
civil status, smoking status, social support level, and previous anxiolytics/antidepressants use 
(all p>0.05, Table 14). The proportions of missing data were similar between the two groups 
(p>0.05, Table 14). 
Table 14.  Baseline characteristics and waiting-time for men with suspected prostate cancer 
(N=185) that were randomized to the usual workup and fast-track workup groups 
  Usual Workup (N=88) Fast-track Workup (N=97)   
Variables N(Missing) Mean(SD) N(Missing) Mean(SD) P 
Age, years  87(1) 67.6(9.59) 97(0) 66.74(7.56) 0.511 
Charlson comorbidity 
score 
88(0) 2.86(1.38) 97(0) 2.78(1.39) 0.691 
PSA level, ng/mL 86(2) 8.58(9.31) 97(0) 6.45(4.33) 0.242 
IPSS_symptom 87(1) 13.84(7.81) 94(3) 12.9(7.93) 0.431 
IPSS_QOL 87(1) 2.45(1.52) 94(3) 2.47(1.56) 0.931 
Waiting-time, days 88(0) 51.35(46.64) 97(0) 11.24(6.53) <0.012 
 
Total N 
(Missing) 
N(%) 
Total N 
(Missing) 
N(%) P 
University education  87(1) 28(32.18) 95(2) 31(32.63) 0.983 
Co-habitation 88(0) 77(87.5) 97(0) 87(89.69) 0.643 
Living in urban areas 88(0) 53(60.23) 97(0) 44(45.36) 0.063 
Pensioners 87(1) 59(67.82) 97(0) 63(64.95) 0.603 
Cigarette smoking 86(2) 
 
91(6) 
  
  Never 
 
39(45.35) 
 
49(53.85) 0.31 
  Former 
 
39(45.35) 
 
38(41.76) 
 
  Current 
 
8(9.3) 
 
4(4.4) 
 
Snuff use 86(2) 
 
90(7) 
  
  Never 
 
54(62.79) 
 
60(66.67) 0.65 
Figure 2. Enrollment of randomized clinical trial for men with suspected prostate cancer, from randomization to first 
urologist visit. 
Randomization  
First urologist visit  Drop-out (N=3) N=97 N=103 
Referral (N=206) 
Usual care (N=100) Fast-track (N=104) 
Un-randomized (N=2) 
Drop-out (N=1) 
 
Questionnaire (N=97) 
Saliva cortisol (N=88) 
ECG (N=96) 
Questionnaire (N=102) 
Saliva cortisol (N=91) 
ECG (N=103) 
Saliva cortisol (N=84) 
ECG (N=82) 
Questionnaire (N=88) Questionnaire (N=98) 
Saliva cortisol (N=90) 
ECG (N=91) 
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  Former 
 
18(20.93) 
 
14(15.56) 
 
  Current 
 
14(16.28) 
 
16(17.78) 
 
Use of antidepressants in 
the past month 
81(7) 3(3.7) 95(2) 6(6.32) 0.513 
Use of anxiolytics in the 
past month 
81(7) 1(1.23) 95(2) 7(7.37) 0.073 
Social support from 
partner 
81(7) 
 
86(11) 
  
  High 
 
53(65.43) 
 
61(70.93) 0.253 
  Moderate 
 
10(12.35) 
 
14(16.28) 
 
  Low 
 
18(22.22) 
 
11(12.79) 
 
Social support from 
others 
84(4) 
 
87(10) 
  
  High 
 
14(16.67) 
 
21(24.14) 0.453 
  Moderate 
 
12(14.29) 
 
13(14.94) 
 
  Low 
 
58(69.05) 
 
53(60.92) 
 
Abbreviation: N, number; SD, standard deviation; PSA, prostate specific antigen; IPSS, international prostate 
symptom score; QOL, quality of life. 
1 P-values based on T-test. 
2 P-values based on Wilcoxon rank sum test. 
3 P-values based on Chi-square test or Fisher’s exact test when expected cell counts less than 5. 
At both randomization and first urologist visit, no clear difference was noticed for self-reported 
distress, HADS depression score, anxiety score, sleep quality, and sleep apnea between the 
intervention and control groups (all p>0.05). However, the fast-track group reported a lower 
self-rated sleep quality score at first urologist visit (2.13 VS 2.49, p<0.05) than usual care 
group. From randomization to first urologist visit, a smaller increase in the self-rated sleep 
quality score was found for the fast-track group than the usual care group (p for difference 
<0.05). A difference was also noticed for the change of HADS depression score from 
randomization to first urologist visit (p for difference <0.05), i.e., the HADS depression score 
showed a small increase in the control group (1.41%) whereas a small decrease in the 
intervention group (-4.71%, Table 15).  
Compared with the usual care group, patients in the fast-track group did no show different heart 
rate, HRV, or SDRR at either randomization or first urologist visit (p>0.05). No difference was 
found for the change of either HRV and SDRR from randomization to first urologist visit 
between these two groups (p>0.05). The saliva cortisol level in both the intervention and 
control groups showed a diurnal rhythm with peaking levels in the morning and the lowest 
levels in the evening (Table 15). However, no clear difference was noted for changes in slope, 
AUCG, or AUCI between the two groups (p>0.05).   
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Table 15.  Changes in self-reported indicators of stress, heart rate variation, and saliva cortisol from randomization to first urologist visit 
among 185 men (88 in the usual care and 97 in the fast-track workup groups) 
 
Randomization (Mean (SD)) 
P2 
First urologist visit (Mean (SD)) 
P2 
Percent change 
P3 P3,4 
Usual Care Fast Track Usual Care Fast Track Usual Care Fast Track 
Distress (NCCN)1  1.83(0.64) 1.91(0.63) 0.38 1.94(0.63) 1.96(0.59) 0.85 10.37 7.21 0.47 0.53 
HADS1           
Anxiety 2.24(0.77) 2.13(0.77) 0.37 2.18(0.77) 2.09(0.77) 0.41 -2.98 -2.05 0.76 0.36 
Depression 1.99(0.65) 1.97(0.67) 0.83 2.00(0.65) 1.85(0.71) 0.14 1.41 -4.71 0.06 0.03 
Sleep           
Sleep quality index1 1.43(0.22) 1.37(0.24) 0.08 1.43(0.20) 1.38(0.22) 0.14 -0.36 0.90 0.50 0.69 
Sleep apnea index1 1.33(0.30) 1.29(0.25) 0.28 1.25(0.26) 1.22(0.21) 0.38 -3.37 -4.05 0.75 0.70 
Self-rated quality 
score 
2.20(0.84) 2.12(0.99) 0.56 2.49(1.07) 2.13(0.97) 0.02 19.23 4.31 0.01 0.008 
ECG           
Heart rate 74(11) 74(12) 0.84 75(13) 77(14) 0.34 1.71 4.70 0.10 0.04 
HRV5 1.30(0.45) 1.45(0.61) 0.06 1.33(0.53) 1.50(0.66) 0.06 6.17 10.14 0.51 0.77 
SDRR5 3.07(0.59) 3.25(0.75) 0.07 3.08(0.75) 3.28(0.84) 0.10 2.28 2.91 0.86 0.71 
Saliva cortisol           
Slope6 
-0.013(-0.097-
0.072) 
 -0.024(-0.119-
0.070) 
0.75 
-0.014(-0.107 - 
0.078) 
-0.028(-0.126 - 
0.069) 
0.66 -8.34 -22.53 0.60 0.94 
AUCG7 1.30(0.75) 1.33(0.76) 0.76 1.26(0.77) 1.34(0.77) 0.51 -2.26 0.93 0.72 0.75 
AUCI8 -3.01(0.17) -3.01(0.17) 0.88 -2.99(0.17) -3.00(0.16) 0.61 0.68 0.40 0.78 0.55 
Abbreviations: SD, standard deviation; NCCN, National Comprehensive Cancer Network; HADS: Hospital Anxiety and Depression Scale; ECG, electrocardiogram; 
HRV, heart rate variation; SDRR, standard deviation of R-R intervals; AUCG, Area under the curve with respect to ground; AUCI, Area under the curve with respect to 
increase. 
1 Square root [√(x+1)] transformed. 
2 P values based on T-test. 
3 P values based comparison between fast-track group and usual care group using generalized linear model. 
4 Model adjusted for age, PSA levels (log- transformed), Charlson comorbidity score, educational level, cohabitation status, living area, cigarette smoking, and snuff use. 
5 Natural log (x+1) transformed. 
6 Linear regression was performed on the three measures of cortisol levels within the day for each individual. The slope presented is the mean of parameter coefficient (and 
95%CI) of the variable indicating time point (i.e., morning, noon, and night). 
7 ln (x) transformed, presented in mean (SD). 
8 -ln (-x+20) transformed, presented in mean (SD). 
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6 DISCUSSION 
6.1 General discussion 
6.1.1 Severe stress response to cancer diagnosis and its related health consequences 
In study I, we used the diagnosis of stress-related mental disorders as the indicator of severe 
stress response to a cancer diagnosis, and investigated its impact on the cancer-specific 
mortality. We found that a first-onset stress-related mental disorder after cancer diagnosis was 
associated with increased cancer-specific mortality. The increased cancer-specific mortality 
was noted for all tested cancer sites. Our findings support the hypothesis that mental 
morbidities affect the survival prospects of patients with cancer. Our findings were supported 
by previous studies where mental disorders were shown to be associated with overall or cancer-
specific mortality [100-103]. In this study, we found that the association of stress-related 
mental disorders with cancer-specific mortality was specifically pronounced among cancer 
patients that had no history of previous mental disorders. The first-onset stress-related mental 
disorders diagnosed after cancer diagnosis might therefore capture the severe stress reaction 
following the diagnosis and while living with cancer.  
From study II, we found that a diagnosis of stress-related mental disorders shortly before and 
after cancer diagnosis increased the rate of hospital admission after cancer diagnosis. An 
increased rate was noted for both any hospitalization and hospitalizations due to specific 
reasons including external injury, infection, and cardiovascular disease. An increased rate was 
noted for all major cancer types, except for melanoma and esophageal, liver and pancreatic 
cancers. Slightly increased rate of hospitalization was also noticed due to other mental 
disorders, which might suggest an increased inpatient care use among individuals with 
impaired mental health in general. However, the magnitude of rate increase was greater among 
cancer patients with stress-related mental disorders, compared to other mental disorders.   
Psychological stress can foster many health consequences in general, through the effects of 
stress hormones and neurotransmitters on disease processes and immune responses. The 
persistent activation of the HPA axis in the chronic stress response probably impairs the 
immune responses and contributes to tumor progression and survival [104]. From 
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experimental studies, the influence of adrenergic and glucocorticoid pathways on tumor 
progression has been noticed from both animal model [105] and human study [106]. In an 
animal model with implanted osteosarcomas and pancreatic adenocarcinomas, tumor was 
found to grow significantly faster in mice with disruption of circadian cortisol rhythms than 
others [107]. Loss of normal cortisol circadian, a similar change as observed in depression 
patients, was also noticed to increase mortality in lung [108] and metastatic breast cancer 
patients [109]. 
In line with previous findings that cancer patients had increased risks for self-harm and 
accidental death, especially shortly after diagnosis [110, 111], we found that stress-related 
mental disorders were associated with an increased rate hospitalization for external injuries 
among patients of all cancer types, except for melanoma. The underlying mechanisms for the 
increased risk of external injury after severe stress are not clear yet. However, mental distress 
[112] and worsening social and physical function secondary to cancer diagnosis might be an 
explanation. The occurrence of stress-related mental disorders could lead to cognitive impact 
and psychiatric symptoms which might contribute to the occurrence of intentional and 
unintentional injuries [113]. 
The increased rate of hospitalization due to infections after a clinical diagnosis of stress-related 
mental disorders was biologically plausible. Psychological stress in relation to caring for a 
demented relative for example was previously noticed to be associated with delayed wound 
healing [114]. Increased risk for wound infection was also found in animals suffering from 
restraint stress [115]. The potential mechanistic links between stress and infection have been 
better investigated. In previous studies, psychological stress was associated with impeded 
immune responses to infectious challenges, and might as a consequence lead to increased risk 
for contagion and prolonged infection episodes [116-118]. Further, depression and anxiety 
was noticed to directly affect the immune system and subsequently regulate the response to 
infections, by for example regulating the secretion of pro-inflammatory cytokines [119].  
The finding that stress-related mental disorders were associated with increased rate of 
hospitalization due to cardiovascular diseases was also in line with previous studies. Various 
stress-related mental disorders, including depression [52, 120] and anxiety [121, 122], have 
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been related to increased risk of coronary artery disease and stroke. Interestingly, increased 
cardiovascular disease-related hospitalization was only found in relation to stress-related 
mental disorders, but not other mental disorders, in this study. This finding can further 
highlight the fact that it might be the severe stress response to the cancer diagnosis, instead of 
the impaired mental health in general, which led to increased risk of cardiovascular diseases 
among cancer patients. 
6.1.2 Role of beta-blocking agents on modulating stress response 
From study III, we found that treatment with cardio-protective beta-blocking agents within 90 
days before and at the time of cancer diagnosis was not associated with reduced risk of severe 
cardiovascular events overall, during the first 90 days after cancer diagnosis. Previous studies 
have shown that cancer patients are at increased risk for cardiovascular events and mortality 
immediately after their cancer diagnosis, which might be attributable to the severe 
psychological stress in relation to the cancer diagnosis [15, 17, 33, 34]. However, cancer 
patients treated with beta-blockers within 90 days before or at the time of cancer diagnosis 
were not found to have decreased risk of severe cardiovascular events compared to other 
cancer patients. In fact, we observed an increased risk of non-fatal cardiovascular events, 
particularly among new users of beta-blockers (i.e., individuals without a previous history of 
beta-blocker use before cancer diagnosis). Patients with beta-blockers had however similar 
risk of fatal cardiovascular events after cancer diagnosis, compared to patients without beta-
blocker use.  
Previous clinical studies have shown that beta-blockers, as a class, are effective in reducing 
mortality among patients with severe cardiovascular diseases, including congenital long QT 
interval syndrome [123], cardiac arrest [124], and ventricular tachycardia [59, 125]. In 
randomized, placebo-controlled trials, consistent and significant reduction of mortality was also 
noticed in relation to beta-blocker use, especially among survivors of acute myocardial 
infarction [60, 126-128]. The fact that cancer patients that used beta-blockers shortly before 
cancer diagnosis had increased risk of non-fatal cardiovascular events, but similar risk of fatal 
cardiovascular events as patients not using beta-blockers might suggest that beta-blockers are 
specifically useful in preventing cardiovascular mortality immediately after cancer diagnosis.  
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The potentially protective role of beta-blockers in preventing fatal cardiovascular events in 
relation to the experience of severe psychological stress is biologically plausible. Such 
biological plausibility might include both the generic cardio-protective and the anti-stress 
properties of the drug. Beta-blocking agents, as a group, have been associated with attenuated 
cardiac stimulation induced by the sympathetic nervous system and ventricular arrhythmia 
[129]. By blocking the beta-adrenergic receptors [130], beta-blockers can reduce the effect of 
catecholamines that increase myocardial oxygen consumption, and decrease oxygen 
requirements of the myocardium by reducing heart rate, systemic arterial pressure, and 
myocardial contractility both at rest and during exercise [131, 132]. Beta-blockers favorably 
affect the biological properties of the dilated cardiomyopathy, by improving intrinsic systolic 
function and increasing diastolic perfusion time [133] to augment or maintain overall 
coronary blood flow. By raising the threshold of ventricular-fibrillation in the ischemic 
myocardium [129], beta-blockers have been found to reduce the occurrence of ventricular 
fibrillation and risk of cardiac arrest during the acute phase of myocardial infarction [134, 
135].  
6.1.3 Fast-track diagnostic workup and psychological stress among men with 
suspected prostate cancer 
Study IV was the first report for a randomized clinical trial, and showed the results between 
the first hospital contact (i.e., randomization) to the first urologist visit among patients 
undergoing a diagnostic workup for prostate cancer. Our findings from this study did not 
indicate a coherent pattern with regard to differences in self-reported indicators and 
physiological measurement of stress, including anxiety, depression, distress, sleep quality, 
sleep apnea, heart rate variability, and the diurnal cortisol slope. However, statistically 
significant changes from randomization to first urologist visit were noticed in depression 
symptoms and the self-rated sleep quality score, indicating a benefit of the fast-track workup 
intervention.  
In earlier observational studies, psychological stress has been noticed to peak before 
receiving the final cancer diagnosis, which may be equal to or even greater than the stress 
experienced after cancer diagnosis [27, 37, 136]. However, few studies had compared the 
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physiological effect of different waiting-times during a prostate diagnostic workup. Our 
findings clearly show the feasibility of a clinical intervention with fast-track diagnostic workup 
for prostate cancer. In this study, almost all men that agreed to participate were randomized 
and only a few dropped out between randomization and the first urologist visit. The study 
further shows how diagnostic workup for prostate cancer can be effectively managed to reduce 
the ordinary waiting-time for urologist visit by an average of 40 days.  
We did not find significant differences of the changes in heart rate variability and diurnal 
cortisol from randomization to the first urologist visit, comparing men in the fast-track 
workup group with men in the usual care group. It is possible that these physiological 
measurements are better in detecting severe or chronic emotional stress [137, 138]. Previous 
neurobiological evidence suggests that heart rate variability is influenced by stress, and is a 
potential assessment of psychological health and stress [138]. However, the sensitivity of 
heart rate variability is influenced by variation of the measurements, including varying 
duration of assessment and the use of time- and frequency-domain analysis [138]. Similarly, 
for cortisol, the correlation between short-term salivary cortisol excretion and self-reported 
psychological stress varies in earlier studies. Flattening of the diurnal cortisol slope, 
indicating a slower rate of decline in cortisol across the day, has been related to both chronic 
and acute psychosocial stress [139]. However, weak correlations between short-term salivary 
cortisol and self-reported stress has been shown both in adults [140] and children [141]. In 
individuals with low levels of stress, saliva cortisol has further been found to have a low 
intra-individual stability [142]. A longer follow-up of the present trial with more participants 
is there needed to explore the differences further. 
6.2 Strength and limitations 
6.2.1 Strength 
The major strength of studies I, II, and III is the large-scale population-based cohort design, 
the prospectively and independently collected data on exposure and outcome, and the 
complete follow-up. In studies I, II, and III, we included all eligible cancer patients diagnosed 
during specific periods in Sweden, using a nationwide cohort study design. Information on 
exposure and outcome was obtained from Swedish national health registers that have been 
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evaluated as both complete and accurate in general. In studies I and II, we obtained the 
information on stress-related mental disorders, cancer mortality, and hospital admission from 
the Patient [77] and Cancer Registers [76]. The information of beta-blocking agent treatment 
and severe cardiovascular events was extracted from the Prescribed Drug [78] and Patient 
Registers in study III. Minimal selection and information biases in the ascertainment of 
exposure and outcome were therefore assured for studies I, II, and III. The major strength of 
study IV is the randomized study design and the systemic assessments of the dynamic 
changes in different aspects of the stress response. Using a feasible fast-tack diagnostic 
workup intervention allowed the comparisons between different waiting-times from first 
hospital contact to first urologist visit.  
6.2.2 Limitations 
Bias 
In studies I and II, we used stress-related mental disorders as the indicator of severe stress 
response in relation to a cancer diagnosis. The mental disorders are a group of diseases with 
an etiology likely including both genetic and non-genetic risk factors. The exposures, first-
onset stress-related mental disorders after cancer diagnosis in study I and stress-related 
mental disorders around cancer diagnosis in study II might therefore potentially reflect the 
severe psychological reaction to receiving a cancer diagnosis, to living a life with cancer and 
its treatment, however, it could also be related to other factors independent of the cancer 
diagnosis-related stress response.  
The severe stress response might include various health consequences and symptoms. Studies 
I and II mainly focused on the clinical diagnosis of stress-related mental disorders, as 
exposure, which likely captured the most severe cases of mental distress and stress symptom. 
In that case, patients who had less severe mental distress that did not lead to a clinical 
diagnosis of stress-related mental disorders would be classified as unexposed. 
In the Prescribed Drug Register, only dispensed beta-blocking agents from pharmacies were 
recorded and used as the exposure of interest, the drugs administrated during hospital 
admissions were not recorded and therefore missing in the analysis of study III. However, in 
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study III, we calculated the treatment period for each beta-blocker dispense and defined the 
cancer patients with a treatment of beta-blockers any time during the 90 days before cancer 
diagnosis as exposed. Considering that the average length of hospital admission was less than 
10 days in Sweden for cancer patients [143], we are confident that we correctly classified the 
exposure status of the participating cancer patients to a large extent. 
In study IV, we only included participants who had completed questionnaires at both 
randomization and first urologist visit in the analysis. As a result the participants with 
missing questionnaire at either visit were excluded. The exclusion could be a source of 
selection bias that may have influenced the estimated associations between the target 
intervention (i.e., fast-track workup) and the self-reported stress response.  
Confounding 
Because of the register-based nature of studies I, II, and III, we had little information on 
potential confounders such as lifestyle factors that might both be related to the exposure and 
the outcome. In studies I and II, lifestyle factors (e.g. smoking and alcohol use) and social 
support, for example, could be a residual confounding for the associations studied. However, 
it is important to note that similar associations were noted for different cancer types, 
regardless of whether or not they had clear links with these factors (e.g. lung cancer and 
prostate cancer).  
In study III, we also did not have detailed information on lifestyle factors (e.g. dietary factors) 
and disease severity (e.g. laboratory results, functional status) that might be related to both 
beta-blocker use and the risk of severe cardiovascular events. As a result, we performed a 
proxy adjustment with a high-dimensional propensity score, including all known factors 
potentially related to both exposure and outcome, which is commonly used in observational 
studies to reduce confounding when benchmarked against randomized trials [88].  
Confounding by indication is another concern in study III, which might have led to a 
potentially underestimated protective effect of beta-blockers on severe cardiovascular events. 
Cancer patients with beta-blocker treatment have on average a higher risk of cardiovascular 
disease than other cancer patients, and patients using beta-blockers might further have a 
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higher risk of severe cardiovascular diseases compared to patients using other 
antihypertensive drugs (e.g., calcium channel blockers). For instance, beta-blocker treatment 
has since 2006 been recommended for patients with complicated and severer cardiovascular 
diseases, including heart failure [144], angina [145], and acute myocardial infarction [146], 
instead as the first-line agents for hypertension [147]. 
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7 CONCLUSIONS 
Cancer patients who were diagnosed with a stress-related mental disorder after cancer 
diagnosis had an increased cancer-specific mortality compared to cancer patients without a 
diagnosis of stress-related mental disorder. The increased cancer-specific mortality was 
mainly attributable to the first-onset stress-related mental disorders after cancer diagnosis. 
The findings support the hypothesis that mental distress may be strongly associated with 
the survival prospects of cancer, and motivate further studies on the underlying mechanisms, 
as well as closer monitoring and treatment of severe stress-related comorbidities in patients 
newly diagnosed with cancer. 
Cancer patients receiving a diagnosis of stress-related mental disorders shortly before or 
after their cancer diagnosis experienced an increased rate of hospital admission afterwards, 
compared to cancer patients without such mental disorder. The increased need for hospital 
admissions among these patients was noticed for all common reasons for inpatient care, 
including external injury, infection, and cardiovascular disease. In the effort to prevent 
adverse health outcomes and improve healthcare among cancer patients, the findings 
suggest the benefit of better psychological management (e.g. surveillance and treatment) 
during cancer diagnostic workup and immediately after the diagnosis of cancer. 
Treatment of beta-blocking agents shortly before and at the time of cancer diagnosis was 
not associated with a decreased hospital admission due to cardiovascular events or 
cardiovascular death, neither shortly after cancer diagnosis nor thereafter. The null 
association between beta-blocker use and fatal cardiovascular events, in clear contrast to the 
positive association noted for non-fatal events, after cancer diagnosis might suggest a specific 
protective role of beta-blockers on cardiovascular mortality. 
The fast-track diagnostic workup, a clinically feasible intervention, for men with suspected 
prostate cancer was not associated with most of the measured biomarkers for stress 
response, including anxiety, distress, heart rate variability, and diurnal cortisol from 
hospital contact to first urologist visit. However, reduced depression symptom and less 
sleep problem were found among men of the intervention group compared to men of the 
usual care group.  
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8 FUTURE PERSPECTIVES 
Cancer patients suffer commonly a severe stress response, related to cancer diagnosis, 
treatment, and the burden of living with cancer. In the thesis, we discussed the impact of 
severe stress response to a cancer diagnosis on the aspects of cancer survival and 
comorbidities. However, the role of stress response to cancer treatment such as surgery, and 
the impact of changed quality of life after cancer treatment on cancer survival, remains 
largely unraveled. Further studies should be performed focusing on the time period before 
and after primary cancer treatment for example.  
Although all cancer patients are exposed to the difficulty of expecting or receiving a cancer 
diagnosis and experience severe psychological stress, only a minority suffers a severe adverse 
health outcome, suggesting that individual vulnerability and resilience factors are important 
[148]. Previous genetic studies have found genetic risk for stress-induced disorders such as 
post-traumatic stress disorders [149]. Genetic studies can therefore be performed to 
investigate the genetic factors related to the severe adverse health outcomes after a cancer 
diagnosis specifically.  
In this thesis work, we did not find protective effect of beta-blocking agent use on acute 
cardiovascular events, after receiving a cancer diagnosis. The null result is most likely due to 
the shortcomings of observational studies, including for example bias by indication. Future 
clinical interventional studies should be performed where the experiment and the reference 
groups are identical apart from the use of beta-blockers. Furthermore, more studies are 
warranted in identifying potential interventions that can help to reduce stress response, 
decrease stress-related comorbidities, and improve cancer survival should be performed. 
In the clinical trial of study IV, we only presented the first report based on the data from first 
hospital contact to first urologist visit. We will enroll more participants and extend the 
follow-up until cancer diagnosis, as well as 6 and 12 months after first urologist visit or 
biopsy. The relation between the fast-track intervention with the stress response during cancer 
diagnostic workup, cancer characteristics, and cancer survival will therefore be further 
investigated.  
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